Cell And Gene Therapy Manufacturing Market Size To Hit USD 106.03 BN By 2033
The global cell and gene therapy manufacturing market size was estimated at USD 9.95 billion in 2023 and is projected to hit around USD 106.03 billion by 2033, growing at a CAGR of 26.7% during the forecast period from 2024 to 2033.
Key Takeaways:
Cell And Gene Therapy Manufacturing Market Growth
The emergence of advanced therapies has played a key role in transforming the treatment paradigm of several life-threatening and rare diseases and in reshaping the biopharmaceutical industry. The rapid growth of the advanced therapy landscape is a key driving factor for the growth of the cell and gene therapy manufacturing market.
The COVID-19 pandemic also served as a driving factor for market growth. Several companies expanded their production capabilities for vector production as well as undertook various strategic initiatives to produce investigational therapies. For instance, in April 2022, BioCardia Inc. declared that the FDA approved the company’s IND applications for COVID-19 stem cell therapy for the treatment of patients recovering from Acute Respiratory Distress due to SARS-CoV-2.
Over the past few years, the healthcare industry has witnessed an improved ratio of clinical success to the number of clinical trials of cellular & gene-modified therapy products. This can be attributed to a better scientific and clinical understanding of safety risks related to the application of these products. As of May 2022, 329 cell and gene therapies are under clinical trial and are expected to increase significantly in the coming years.
Significant investments by government authorities and key market players are other factors fueling growth for cell and gene therapy manufacturing. Around USD 2.3 billion was invested in gene therapy companies over the last decade. This significantly high amount indicates that global pharmaceutical and biotechnology companies are investing in leading gene therapy companies. Major service providers, including CDMOs/CMOs, and in-house manufacturers consider gene & cell therapy as an active area of investment.
Cell And Gene Therapy Manufacturing Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 12.60 Billion |
| Market Size by 2033 | USD 106.03 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 26.7% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Therapy type, scale, mode, workflow, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Lonza; Bluebird Bio; Catalent Inc.; F. Hoffmann-La Roche Ltd.; Samsung Biologics; Boehringer Ingelheim; Cellular Therapeutics; Hitachi Chemical Co., Ltd.; Bluebird Bio Inc.; Takara Bio Inc.; Miltenyi Biotec; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Novartis AG; Merck KGaA; Wuxi Advanced Therapies |
Segments Insights:
Therapy Type Insights
The cell therapy manufacturing segment dominated the market with a revenue share of 60.19% in 2023. The higher market share is attributed to the increasing number of products entering the marketplace and the high number of ongoing clinical trials. More than 360 clinical trials focusing on CAR-T cell therapies and other cell-based therapies are being studied to decipher the potential of these therapies for the treatment of various disease indications. Thus, the demand for advanced therapy manufacturing services is expected to increase in the coming years.
The gene therapy segment is expected to expand by a significant CAGR during the forecast period. With a large number of products currently in clinical trials, production process improvement has become a major need for the gene therapy manufacturing market. With an increase in investments from players and the clinical success of more products, several gene therapy companies are focusing on manufacturing and commercialization. Evaluating the existing process and its scalability, as well as for deciding on in-house or outsourced manufacturing, are some of the major factors to be considered while designing the manufacturing process for gene therapy products. Some of the key global companies are undertaking various strategic initiatives to boost their presence in the gene therapy manufacturing market. For instance, in September 2020, Pfizer collaborated with Vivet Therapeutics to manufacture Wilson's disease candidate.
Scale Insights
The pre-commercial/R&D scale manufacturing segment captured a significant revenue share of 73.34% in 2023. Certain factors such as the robust and constantly growing pipeline of gene and cell therapies along with the rise in investments are expected to have a positive impact on the segment growth. Till 2022, more than 2,073 clinical trials were ongoing for various cell therapies. Furthermore, according to an article published in September 2021, over 200 gene therapies are under clinical trials, which could translate to up to 40 new products being approved for clinical use in the next decade.
The commercial-scale manufacturing segment is projected to have the highest CAGR during the forecast period. With the increasing number of regulatory approvals for gene and cell therapy products, the demand for commercial production of these therapies is increasing rapidly. The major market players such as Thermo Fisher Scientific and AGC Biologics are undertaking various strategic initiatives to fulfill the changing market demands. For instance, in February 2022, Thermo Fisher Scientific launched new Patheon Commercial Packaging Services for cell and gene therapy across the U.S. and Europe. This integrated solution combines logistics, serialization compliance, and distribution globally. Such factors are expected to offer a favorable environment for segment growth by 2033.
Mode Insights
The contract manufacturing mode segment held the highest revenue share of 67.13% in 2023. With the growing demand for cell and gene therapies, the shortage of manufacturing capacity is creating growth opportunities for contract manufacturing service providers. As the market for cell and gene therapies is non-standardized and rapidly changing, outsourcing to a contract manufacturing service provider is expected to provide a competitive advantage in terms of experience and expertise. According to an article published in March 2020, approximately 35% of the process is outsourced with traditional biologics and more than 65% of the manufacturing process for cell and gene therapies is outsourced. This can be attributed to the fact that around two-thirds of the innovation in this space is achieved by small firms that lack the capacity, expertise, and resources for the commercialization of these products. The constantly growing clinical pipeline is another contributing factor expected to accelerate segment growth.
The in-house manufacturing segment is likely to register a considerable CAGR during the forecast period. The academic institutes with personalized patient treatment programs, as well as the presence of a substantial number of entities with large capital, are the largest contributors to this segment. Moreover, advantages over contract manufacturing are also expected to boost segment growth. Small biotechnology companies developing cell and gene therapies lack resources, capacity, and infrastructure, leading to strategic partnerships with contract manufacturers. This factor is expected to boost segment growth in the coming years. Moreover, the investments in this area are expanding by 30-35% per year, further propelling the market growth.
Workflow Insights
On the basis of workflow, the process development segment accounted for a significant revenue share of 17.57% in 2023. With an increasing number of therapies advancing from clinical trials to regulatory approval, the development of well-characterized and robust methods for cell therapy production has become increasingly important. Process development strategies provide efficiency while improving the quality and safety profiles of candidate programs. Process development can be applied to all process elements, such as cell characterization, cell isolation, optimization of cell culture media, removal of impurities, and scale-up.
The vector development segment is estimated to register the fastest CAGR during the forecast period. The high penetration of manufacturing services in this space is the major factor contributing to the segment growth. With a growing market for gene therapies, the demand for viral vectors is increasing. Viral vectors have been used for the treatment of various disorders, such as metabolic, cardiovascular, muscular, infectious, hematologic, and ophthalmologic, as well as various types of cancer. The most widely used viral vectors are adenoviral, retroviral, AAV, lentiviral, and herpes simplex virus.
Regional Insights
North America accounted for the highest revenue share of 48.32% in 2023. This can be attributed to the growing engagement of entities in research and product development in gene and cell therapy, coupled with a substantial number of contract development organizations in the region. In addition, homegrown companies are expanding their manufacturing facilities in the region.
Asia Pacific is anticipated to be a growing market for cell and gene therapy manufacturing. The region accounted for a 21.11% revenue share in 2023 and is estimated to witness the fastest growth with a significant CAGR from 2023 to 2030. Over the past several years, the cell therapy market has gained momentum in Asia. This can be attributed to the establishment of accelerated approval pathways, increasing healthcare needs, and growing private and government investments.
Key Companies & Market Share Insights
The key entities in the market are undertaking several strategic initiatives such as licensing, partnership, and mergers and acquisitions to expand their market presence. Over the last few years, the market witnessed various remarkable mergers and acquisitions. For instance, in January 2022, Thermo Fisher acquired PeproTech, a manufacturer of recombinant proteins such as growth factors and cytokines, for USD 1.85 billion:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Cell And Gene Therapy Manufacturing market.
By Therapy Type
By Scale
By Mode
By Workflow
By Region
Chapter 1 Cell And Gene Therapy Manufacturing Market: Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 nova one advisor Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details Of Primary Research
1.5 Information Or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.8 Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
Chapter 2 Cell And Gene Therapy Manufacturing Market: Executive Summary
2.1 Competition Milieu
2.2 Segment Outlook
2.3 Market Summary, 2024 (USD Million)
Chapter 3 Cell And Gene Therapy Manufacturing Market: Variables, Trends, & Scope
3.1 Market Segmentation
3.2 Parent Market Lineage
3.3 Ancillary Market Lineage
3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2024
3.5 Market Dynamics
3.5.1 Market Drivers Analysis
3.5.1.1 Growing Pipeline Of Cell And Gene Therapy
3.5.1.2 Supportive Regulatory Bodies
3.5.1.3 Increase In Investment By Government And Private Players
3.5.2 Market Restraint Analysis
3.5.2.1 Technological Challenges Associated With Manufacturing
3.5.2.2 High Cost Of Manufacturing
3.5.3 Market Opportunity Analysis
3.5.3.1 Rising Pressure On Drug Developers/Manufacturers To Meet The Growing Market Demand
3.5.3.2 Expansion In Potential Markets Such As Asia Pacific And Latin America
3.5.4 Market Challenge Analysis
3.5.4.1 Lack Of Manufacturing Capacity
3.6 Swot Analysis; By Factor (Political & Legal, Economic, And Technological)
3.7 Porter’s Five Forces Analysis
3.8 Major Deals And Strategic Alliances Analysis
3.8.1 Mergers And Acquisitions
3.8.2 Technological Collaborations
3.8.3 Licensing And Partnerships
3.9 Covid-19 Impact Analysis
3.9.1 Challenge Analysis
3.9.2 Opportunity Analysis
3.9.3 Key Developments And Activities
Chapter 4 Focus On Manufacturers
4.1 Cell And Gene Therapy Manufacturing
4.1.1 Facility Expansion For Cell And Gene Therapies
4.1.2 Major Deals And Strategic Alliances Analysis
4.1.3 Mergers And Acquisitions
4.1.4 Technological Collaborations And Partnerships
4.1.5 Product Approvals And Launch
4.2 Cost Of Goods Analysis In Cell And Gene Therapy Manufacturing
4.2.1 Overall Cost Of Goods Analysis
4.2.2 Raw Material
4.2.3 Labor Costs
4.2.4 Process Costs
4.2.5 Cost Models
4.2.6 Campaign Model
4.2.7 Day Rate Model
4.2.8 Hybrid Model
4.2.9 Cost Of Goods Analysis, By Technique
4.2.10 Materials
4.2.11 Equipment
4.2.12 Personnel
4.2.13 Facility
Chapter 5 Therapy Type Business Analysis
5.1 Cell and Gene Therapy Manufacturing Market: Therapy Type Movement Analysis
5.2 Cell Therapy Manufacturing
5.2.1 Cell Therapy Manufacturing Market Estimates And Forecast, 2024 - 2033 (Volume, Number Of Doses)
5.2.2 Stem Cell Therapy
5.2.3 Cell Therapy Manufacturing Market Estimates And Forecast For Stem Cell Therapy, 2024 - 2033 (Volume, Number Of Doses)
5.2.4 Non-Stem Cell Therapy
5.2.5 Cell Therapy Manufacturing Market Estimates And Forecast For Non-Stem Cell Therapy, 2024 - 2033 (Volume, Number Of Doses)
5.3 Gene Therapy Manufacturing
5.3.1 Gene Therapy Manufacturing Market Estimates And Forecast, 2024 - 2033 (Volume, Number Of Doses)
Chapter 6 Manufacturing Scale Business Analysis
6.1 Cell And Gene Therapy Manufacturing Market: Scale Movement Analysis
6.2 Precommercial/R&D Scale Manufacturing
6.2.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Precommercial/R&D Scale Manufacturing, 2024 - 2033
6.3 Commercial-Scale Manufacturing
6.3.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Commercial-Scale Manufacturing, 2024 - 2033
Chapter 7 Mode Business Analysis
7.1 Cell And Gene Therapy Manufacturing Market: Mode Movement Analysis
7.2 Contract Manufacturing
7.2.1 Cell And Gene Therapy Manufacturing Market For Contract Manufacturing, 2024 - 2033 (Volume, Number Of Doses)
7.3 In-House Manufacturing
7.3.1 Cell And Gene Therapy Manufacturing Market For In-House Manufacturing, 2024 - 2033 (Volume, Number Of Doses)
Chapter 8 Workflow Business Analysis
8.1 Cell And Gene Therapy Manufacturing Market: Workflow Movement Analysis
8.2 Cell Processing
8.2.1 Cell And Gene Therapy Manufacturing Market For Cell Processing, 2024 - 2033
8.3 Cell Banking
8.3.1 Cell And Gene Therapy Manufacturing Market For Cell Banking, 2024 - 2033
8.4 Process Development
8.4.1 Cell And Gene Therapy Manufacturing Market For Process Development, 2024 - 2033
8.5 Fill And Finish Operations
8.5.1 Cell And Gene Therapy Manufacturing Market For Fill And Finish Operations, 2024 - 2033
8.6 Analytical And Quality Testing
8.6.1 Cell And Gene Therapy Manufacturing Market For Analytical And Quality Testing, 2024 - 2033
8.7 Raw Material Testing
8.7.1 Cell And Gene Therapy Manufacturing Market For Raw Material Testing, 2024 - 2033
8.8 Vector Production
8.8.1 Cell And Gene Therapy Manufacturing Market For Vector Production, 2024 - 2033
8.9 Others
8.9.1 Cell And Gene Therapy Manufacturing Market For Others, 2024 - 2033
Chapter 9 Regional Business Analysis
9.1 North America
9.1.1 Swot Analysis
9.1.1.1 North America Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.1.2 U.S.
9.1.2.1 Key Country Dynamics
9.1.2.2 Target Disease Prevalence
9.1.2.3 Competitive Scenario
9.1.2.4 Regulatory Framework
9.1.2.5 Reimbursement Scenario
9.1.2.6 U.S. Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.1.3 Canada
9.1.3.1 Key Country Dynamics
9.1.3.2 Target Disease Prevalence
9.1.3.3 Competitive Scenario
9.1.3.4 Regulatory Framework
9.1.3.5 Reimbursement Scenario
9.1.3.6 Canada Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2 Europe
9.2.1 Swot Analysis
9.2.1.1 Europe Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2.2 Germany
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 Germany Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2.3 U.K.
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 UK Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2.4 France
9.2.4.1 Key Country Dynamics
9.2.4.2 Target Disease Prevalence
9.2.4.3 Competitive Scenario
9.2.4.4 Regulatory Framework
9.2.4.5 Reimbursement Scenario
9.2.4.6 France Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2.5 Italy
9.2.5.1 Key Country Dynamics
9.2.5.2 Target Disease Prevalence
9.2.5.3 Competitive Scenario
9.2.5.4 Regulatory Framework
9.2.5.5 Reimbursement Scenario
9.2.5.6 Italy Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2.6 Spain
9.2.6.1 Key Country Dynamics
9.2.6.2 Target Disease Prevalence
9.2.6.3 Competitive Scenario
9.2.6.4 Regulatory Framework
9.2.6.5 Reimbursement Scenario
9.2.6.6 Spain Cell & Gene Therapy Market Estimates And Forecasts, 2024 - 2033
9.2.7 Denmark
9.2.7.1 Key Country Dynamics
9.2.7.2 Target Disease Prevalence
9.2.7.3 Competitive Scenario
9.2.7.4 Regulatory Framework
9.2.7.5 Reimbursement Scenario
9.2.7.6 Denmark Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2.8 Sweden
9.2.8.1 Key Country Dynamics
9.2.8.2 Target Disease Prevalence
9.2.8.3 Competitive Scenario
9.2.8.4 Regulatory Framework
9.2.8.5 Reimbursement Scenario
9.2.8.6 Sweden Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.2.9 Norway
9.2.9.1 Key Country Dynamics
9.2.9.2 Target Disease Prevalence
9.2.9.3 Competitive Scenario
9.2.9.4 Regulatory Framework
9.2.9.5 Reimbursement Scenario
9.2.9.6 Norway Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.3 Asia Pacific
9.3.1 SWOT Analysis
9.3.1.1 Key Region Dynamics
9.3.1.2 Asia Pacific Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.3.2 Japan
9.3.2.1 Target Disease Prevalence
9.3.2.2 Competitive Scenario
9.3.2.3 Regulatory Framework
9.3.2.4 Reimbursement Scenario
9.3.2.5 Japan Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.3.3 China
9.3.3.1 Target Disease Prevalence
9.3.3.2 Competitive Scenario
9.3.3.3 Regulatory Framework
9.3.3.4 Reimbursement Scenario
9.3.3.5 China Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.3.4 India
9.3.4.1 Target Disease Prevalence
9.3.4.2 Competitive Scenario
9.3.4.3 Regulatory Framework
9.3.4.4 Reimbursement Scenario
9.3.4.5 India Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.3.5 South Korea
9.3.5.1 Target Disease Prevalence
9.3.5.2 Competitive Scenario
9.3.5.3 Regulatory Framework
9.3.5.4 Reimbursement Scenario
9.3.5.5 South Korea Cell & Gene Therapy Market Estimates And Forecasts, 2024 - 2033
9.3.6 Australia
9.3.6.1 Target Disease Prevalence
9.3.6.2 Competitive Scenario
9.3.6.3 Regulatory Framework
9.3.6.4 Reimbursement Scenario
9.3.6.5 Australia Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.3.7 Thailand
9.3.7.1 Target Disease Prevalence
9.3.7.2 Competitive Scenario
9.3.7.3 Regulatory Framework
9.3.7.4 Reimbursement Scenario
9.3.7.5 Thailand Cell & Gene Therapy Market Estimates And Forecasts, 2024 - 2033
9.4 Latin America
9.4.1 Swot Analysis:
9.4.2 Key Regional Dynamics
9.4.2.1 Latin America Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.4.3 Brazil
9.4.3.1 Target Disease Prevalence
9.4.3.2 Competitive Scenario
9.4.3.3 Regulatory Framework
9.4.3.4 Reimbursement Scenario
9.4.3.5 Brazil Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.4.4 Mexico
9.4.4.1 Target Disease Prevalence
9.4.4.2 Competitive Scenario
9.4.4.3 Regulatory Framework
9.4.4.4 Reimbursement Scenario
9.4.4.5 Mexico Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.4.5 Argentina
9.4.5.1 Target Disease Prevalence
9.4.5.2 Competitive Scenario
9.4.5.3 Regulatory Framework
9.4.5.4 Reimbursement Scenario
9.4.5.5 Argentina Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
9.5 Middle East & Africa (MEA)
9.5.1 Swot Analysis
9.5.2 Key Regional Dynamics
9.5.2.1 Middle East & Africa Cell & Gene Therapy Market Estimates And Forecasts, 2024 - 2033
9.5.3 South Africa
9.5.3.1 Target Disease Prevalence
9.5.3.2 Competitive Scenario
9.5.3.3 Regulatory Framework
9.5.3.4 Reimbursement Scenario
9.5.3.5 South Africa Cell & Gene Therapy Market Estimates And Forecasts, 2024 - 2033
9.5.4 Saudi Arabia
9.5.4.1 Target Disease Prevalence
9.5.4.2 Competitive Scenario
9.5.4.3 Regulatory Framework
9.5.4.4 Reimbursement Scenario
9.5.4.5 Saudi Arabia Cell & Gene Therapy Market Estimates And Forecasts, 2024 - 2033
9.5.5 UAE
9.5.5.1 Target Disease Prevalence
9.5.5.2 Competitive Scenario
9.5.5.3 Regulatory Framework
9.5.5.4 Reimbursement Scenario
9.5.5.5 UAE Cell & Gene Therapy Market Estimates And Forecasts, 2024 - 2033
9.5.6 Kuwait
9.5.6.1 Target Disease Prevalence
9.5.6.2 Competitive Scenario
9.5.6.3 Regulatory Framework
9.5.6.4 Reimbursement Scenario
9.5.6.5 Kuwait Cell & Gene Therapy Market Estimates and Forecasts, 2024 - 2033
Chapter 10 Competitive Landscape
10.1 Strategy Framework
10.2 Market Participation Categorization
10.3 Company Profiles
10.3.1 Thermo Fisher Scientific, Inc.
10.3.1.1 Company Overview
10.3.1.2 Financial Performance
10.3.1.3 Product Benchmarking
10.3.1.4 Strategic Initiatives
10.3.2 Merck Kgaa
10.3.2.1 Company Overview
10.3.2.1.1 Milliporesigma
10.3.2.2 Financial Performance
10.3.2.3 Product Benchmarking
10.3.2.4 Strategic Initiatives
10.3.3 Lonza
10.3.3.1 Company Overview
10.3.3.2 Financial Performace
10.3.3.3 Product Benchmarking
10.3.3.4 Strategic Initiatives
10.3.4 Catalent, Inc.
10.3.4.1 Company Overview
10.3.4.2 Financial Performance
10.3.4.3 Product Benchmarking
10.3.4.4 Strategic Initiatives
10.3.5 Takara Bio, Inc.
10.3.5.1 Company Overview
10.3.5.2 Financial Performance
10.3.5.3 Product Benchmarking
10.3.5.4 Strategic Initiatives
10.3.6 F. Hoffmann-La Roche Ltd.
10.3.6.1 Company Overview
10.3.6.2 Financial Performance
10.3.6.3 Product Benchmarking
10.3.6.4 Strategic Initiatives
10.3.7 Wuxi Advanced Therapies
10.3.7.1 Company Overview
10.3.7.2 Financial Performance
10.3.7.3 Product Benchmarking
10.3.7.4 Strategic Initiatives
10.3.8 Samsung
10.3.8.1 Company Overview
10.3.8.1.1 Samsung Biologics
10.3.8.2 Company Overview
10.3.8.3 Financial Performance
10.3.8.4 Product Benchmarking
10.3.8.5 Strategic Initiatives
10.3.9 Boehringer Ingelheim International Gmbh
10.3.9.1 Company Overview
10.3.9.2 Financial Performance
10.3.9.3 Product Benchmarking
10.3.9.4 Strategic Initiatives
10.3.10 Novartis Ag
10.3.10.1 Company Overview
10.3.10.2 Financial Performance
10.3.10.3 Product Benchmarking
10.3.10.4 Strategic Initiatives
10.3.11 Hitachi Chemical Co., Ltd. (Showa Denko Materials Co Ltd)
10.3.10.1 Company Overview
10.3.10.1.1 Apceth Biopharma
10.3.10.2 Company Overview
10.3.10.3 Financial Performance
10.3.10.4 Product Benchmarking
10.3.10.5 Strategic Initiatives
10.3.12 Cellular Therapeutics
10.3.12.1 Company Overview
10.3.12.2 Product Benchmarking
10.3.13 Miltenyi Biotech
10.3.13.1 Company Overview
10.3.13.2 Financial Performance
10.3.13.3 Product Benchmarking
10.3.13.4 Strategic Initiatives
10.3.14 Bluebird Bio Inc.
10.3.14.1 Company Overview
10.3.14.2 Financial Performance
10.3.14.3 Product Benchmarking
10.3.14.4 Strategic Initiatives
10.4 Recent Developments And Impact Analysis By Key Market Participants
10.5 Company Mapping
10.6 Vendor Landscape
10.6.1 List Of Key Distributors And Channel Partners
10.6.2 Key Company Market Share Analysis, 2024
10.7 Public Companies
10.7.1 Company Market Position Analysis
10.7.2 Competitive Dashboard Analysis
10.8 Private Companies
10.8.1 List Of Key Emerging Companies
10.8.2 Regional Network Map
10.8.3 Company Market Position Analysis
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers